Zenda S, et al. - In patients with head and neck cancer, researchers seek to describe how topical steroids benefit basic nursing care for radiation dermatitis caused by chemoradiotherapy via conducting a multicenter 2-arm randomized double-blinded placebo-controlled phase 3 trial in Japan between May 2017 and April 2019. Eligibility criteria includes patients scheduled to receive definitive or postoperative chemoradiotherapy for head and neck cancer. According to the findings, evidence supporting the benefit of adding topical steroids in general nursing care for radiation dermatitis induced by high-dose irradiation with chemotherapy is inadequate up until this point. This study plans to clarify these benefits.